Clinical Trials Browser

Phase 2 × Splenomegaly × Nivolumab × Clear all

NCT02421354 2019-05-15

Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Post-Polycythemia Vera Myelofibrosis

Phase 2 Terminated

8 enrolled 7 charts

Hepatomegaly, Polycythemia Vera, Splenomegaly, Primary Myelofibrosis